EMA Refused: Qsiva (phentermine;topiramate) — Vivus BV

View source ↗

Summary

The EMA refused approval for Qsiva (phentermine and topiramate) for obesity, with Vivus BV as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Qsiva (phentermine;topiramate)

Snippet

Status: Refused. Therapeutic area: Obesity. MAH: Vivus BV. Decision date: 14/05/2013